Sanofi-Genzyme joins Immune Design syndicate

Immune Design, a US-based biotechnology company focused on the development of immune-based therapies for cancer and other chronic conditions, has closed a series C financing of up to $49m, led by The Column Group, a biotechnology-focused venture capital firm, and new investor, private equity fund Topspin Partners; the round included new investor Sanofi-Genzyme BioVentures, the $100m corporate venture capital fund of France-based pharmaceutical company Sanofi and its US-based subsidiary Genzyme, together with existing investors Alta Partners, Versant Ventures, Osage Partners…